The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe.
Cost-effectiveness analyses are usually not directly comparable between countries because of differences in analytical and modelling assumptions. We investigated the cost-effectiveness of rotavirus vaccination in five European Union countries (Belgium, England and Wales, Finland, France and the Netherlands) using a single model, burden of disease estimates supplied by national public health agencies and a subset of common assumptions. Under base case assumptions (vaccination with Rotarix, 3% discount rate, health care provider perspective, no herd immunity and quality of life of one caregiver affected by a rotavirus episode) and a cost-effectiveness threshold of euro30,000, vaccination is likely to be cost effective in Finland only. However, single changes to assumptions may make it cost effective in Belgium and the Netherlands. The estimated threshold price per dose for Rotarix (excluding administration costs) to be cost effective was euro41 in Belgium, euro28 in England and Wales, euro51 in Finland, euro36 in France and euro46 in the Netherlands.
Jit
Mark
M
Health Economics Unit, University of Birmingham, United Kingdom. m.jit@bham.ac.uk
Bilcke
Joke
J
Mangen
Marie-Josée J
MJ
Salo
Heini
H
Melliez
Hugues
H
Edmunds
W John
WJ
Yazdan
Yazdanpanah
Y
Beutels
Philippe
P
D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D005060:Europe / Q000453:epidemiology; D006801:Humans; D032521:Immunity, Herd; D018803:Models, Economic; D019057:Quality-Adjusted Life Years; D012400:Rotavirus Infections / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control*; D022243:Rotavirus Vaccines / Q000191:economics*; D014613:Vaccines, Attenuated / Q000191:economics
C492457:RIX4414 vaccine; D022243:Rotavirus Vaccines; D014613:Vaccines, Attenuated